Pesquisar um ensaio clínico
Outras opções de pesquisa
9 Resultado(s)
Ensaio em fase de recrutamento = ; Ensaio a decorrer =
; Financiado por um membro do IRDiRC =
; Membro de uma ERN =
Ensaio (s) clínico (s) nacional (is)

ESPANHA
Madrid
MADRID

Setmelanotide (RM-493): Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo

ESPANHA
Madrid
MADRID
A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and AlstrC6m syndrome (AS) Patients with Moderate to Severe Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo

FRANCA
OCCITANIE
TOULOUSE

OXYJEUNE : Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years (Phase III)
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi

FRANCA
OCCITANIE
TOULOUSE

OT2SUITE : Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi

PAISES BAIXOS
Zuid-Holland
ROTTERDAM

Dutch Growth Hormone Cohort study in children with Prader-Willi syndrome: Long-term effects on growth, body composition, activity level and psychosocial development
Stichting Kind en Groei

REINO UNIDO
Merseyside
LIVERPOOL
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
Fazakerley Hospital
University Hospital Aintree - Diabetes and Endocrinology

REINO UNIDO
West Midlands
BIRMINGHAM

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic

SUICA
Suisse Romande
GENÈVE

Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome
UNIGE
Service Médico-Pédagogique Département de Psychiatrie
Ensaio (s) clínico (s) multinacional (ais)

REINO UNIDO
Greater London
LONDON